Pharmacies reported a shortage of drugs for IVF

Russian pharmacy chains reported a shortage, and in some cases the absence of hormonal drugs Divigel, Proginova and Estrogel,used in in vitro fertilization

In Russian pharmacy chains, there is a shortage of hormonal drugs Divigel, Proginova and Estrogel, which are often used in in vitro fertilization (IVF). This was reported to RBC by Nelli Ignatieva, executive DIRECTOR of the Russian Association of Pharmacy Chains.

“There are deliveries [of all three drugs], but in terms of their volume to the retail network, we want more,” she explained.

See also The moment of the explosion in Crimea 00:25

The regional manager of the Evalar pharmacy chain, Yulia Parkhomova, in turn, stated that the last deliveries of Divigel, Proginova and Estrogel drugs were in April-June 2022. “At the moment, they are not available from suppliers for reasons unknown to us,” she said.

Director General of Zdravcity LLC Boris Popov told RBC that these drugs are currently not available for sale on the Zdravcity marketplace. “The rest were sold during the first week of August. There is a high demand for Estrogel, which the supplier, due to production restrictions, is not yet ready to fully meet. Small batches of goods are on sale. The Finnish manufacturer of the Divigel drug has temporarily suspended deliveries to RUSSIA,” he said.

According to him, there are problems with the presence of components in the production of Proginova, so the delivery should be expected only in September. At the same time, Popov pointed to the presence of analogues that can also be used in IVF procedures - these are Femoston, Angelik and Zoeli.

Natalya Burdina, commercial director of the Rigla pharmacy chain, told RBC that “in the distribution and retail segments of the pharmaceutical market, there is a shortage of hormonal drugs Proginova, Estrogel, Divigel”. At the moment, the pharmacies of the "Rigla" network have their balances in small volumes. The manufacturer of the drug "Divigel" reports planned deliveries to warehouses in late August - early September. Estrogel and Proginova were shipped to distributors at the end of July, there was no information about the date of the resumption of the supply of Estrogel, the batch of Proginova is expected in September.”

Earlier, the E1 portal reported that there are practically no drugs necessary for IVF in pharmacies. Obstetrician-gynecologist Ksenia Sukhova explained to the publication that it is impossible to do without hormonal drugs in IVF programs, and the most common ones are Proginova, Estrogel and Divigel. “Today in our country there are problems with the supply of drugs. But, as a rule, it is possible to find their analogues in pharmacy chains, sometimes in neighboring satellite cities, ”she explained.

Read on RBC Pro Pro Threat to marketplaces: why TELEGRAM can become the onewhat Sberbank failed to do Articles Pro Car dealers will have to cut staff.Who is the first in the risk zone Forecasts Pro Builders have begun salary races for workers.How the industry is changing Forecasts Pro x The Economist The global smartphone market has stopped growing.How Apple's business will changeIs it now possible for residents of the Russian Federation to transfer currency abroad Articles Pro Will banking transactions be protected after the departure of the French Thales ArticlesPro Bypassing sanctions: how to securely transfer money abroad or to Russia Articleshow to securely transfer money abroad or to Russia

RBC turned to the Russian Ministry of HEALTH for comment.

The Ministry of Education and Science estimated drug sovereignty at ₽200 billion Society

After the imposition of sanctions against Russia, due to the military operation in Ukraine, there were interruptions in the supply of some medicines: pharmacy chains and patients reported interruptions in imported methotrexate for rheumatic diseases, drugs with levodopa for those suffering from Parkinson's disease, and drugs for hypothyroidism and epilepsy. After media reports, the Ministry of Health announced the elimination of the shortage of drugs for the treatment of thyroid diseases, and instructed domestic manufacturers of drugs for Parkinson's disease to increase output.

The Ministry of Education and Science previously reported that today the share of foreign drug manufacturers in the Russian market in monetary terms is 55% with a total market volume of 2.3 trillion rubles, in quantitative terms - 33% of 6.5 billion packages. They also developed a concept according to which Russia can achieve drug sovereignty, which assumes that drugs produced in the country will occupy an 85% share in packages, and also EXPORT at least 50 of its own original drugs by 2030. This, according to the ministry, will require at least 200 billion rubles.